Nanoassemblr Blaze mRNA Vaccine Demo

A candidate drug must be shown to be both potent and non-toxic in relevant models. While early early screening in murine models is enough to begin a program, the demands for data from larger models is increasing. Traditionally, process development for nanomedicine production at an intermediate scale is a barrier to this work. However, with NxGen technology on the NanoAssemblr Blaze, these important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.

NxGen Technology delivers a scalable means to perform the critical particle formation step in a nanomedicine development process. However, success of a program requires a scalable, end-to-end process. Using the NanoAssemblr Blaze, process development can be conducted on both the upstream and downstream portions, from material preparation to buffer exchange, filtering and analytics, to ensure that a program is ready to quickly accelerate to the clinic.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online